NCT04821622 2026-03-11
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
Clinical Trials
25 trialsNCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT06551324 2026-03-04
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT07028853 2026-03-04
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT04455750 2026-02-05
CASPAR
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT02003924 2026-01-27
PROSPER
Pfizer
Phase 3 Completed
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04647526 2026-01-13
SPLASH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT02194842 2025-09-19
PEACE III
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT05204927 2025-07-31
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Curium US LLC
Phase 3 Active not recruiting
NCT03834493 2025-07-18
KEYNOTE-641
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02319837 2025-07-08
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT02446444 2025-05-30
ENZARAD
University of Sydney
Phase 3 Active not recruiting
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT02446405 2025-02-06
ENZAMET
University of Sydney
Phase 3 Active not recruiting
NCT04409288 2024-01-05
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Chinese University of Hong Kong
Phase 3 Terminated
NCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT02438007 2023-03-15
ARMOR3-SV
LTN PHARMACEUTICALS, INC.
Phase 3 Terminated
NCT01212991 2020-03-17
PREVAIL
Pfizer
Phase 3 Completed